On November 2, 2015 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, reported that its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) to be held from November 5 – 9, 2015, in Boston, MA (Press release, Curis, NOV 2, 2015, View Source [SID:1234507871]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Curis’ collaborator, Aurigene will present data from CA-170 (previously AUPM-170), a first-in-class oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) as well as from the interleukin-1 receptor association kinase4 (IRAK4) inhibitor program. Curis recently exercised options to license both these programs under a collaboration agreement with Aurigene established earlier this year.

Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.

Poster Presentations

Date/Time: Friday, Nov. 6, 2015, 12:15 PM – 3:15 PM
Session Title: Immune Modulators
Presentation Title: First-in-class orally available immune checkpoint antagonists for cancer therapy
Location: Session A, Hall C-D
Abstract Number: A96

Date/Time: Sunday, Nov. 8, 2015, 12:30 PM – 3:30 PM
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Presentation Title: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models
Location: Session C, Hall C-D
Abstract Number: C191

On November 2, 2015 Foundation Medicine, Inc. (NASDAQ:FMI) reported that F. Hoffmann La-Roche’s affiliate in Israel, Roche Pharmaceuticals (Israel) Ltd., will commence commercial activities in support of its suite of molecular information products (Press release, Foundation Medicine, NOV 2, 2015, View Source [SID:1234507872]). As part of the ex-US collaboration between Foundation Medicine and Roche, Roche Israel will act as the exclusive distributor of Foundation Medicine’s current products and services in Israel commencing as of October 24, 2015. The companies will also cooperate on the continued development of Foundation Medicine’s groundbreaking molecular information products to drive precision medicine and deliver improved clinical outcomes in cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to initiate our ex-US collaboration with Roche Israel and bring a complete suite of molecular information products to the oncology community in Israel," stated David Daly, Chief Commercial Officer of Foundation Medicine. "Roche’s strong market presence will be a key differentiator for Foundation Medicine’s products, and ultimately will drive increased access to critical molecular information solutions that empower cancer care teams to make informed therapeutic treatment decisions and positively impact clinical outcomes for patients."

Roche Israel will commence commercial activities for Foundation Medicine’s end-to-end molecular information solutions, including FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies and sarcomas, and FoundationICE.

Avi Danziger, General Manager of Roche Israel stated: "The combination of Foundation Medicine’s molecular information suite of products and our expertise in oncology drug development supports our unified quest to tailor the best care and treatment for patients and take a leading position in doing now what patients need next."

On November 1, 2015 Calithera Biosciences presented the corporate presentation (Presentation, Calithera Biosciences, NOV 1, 2015, View Source [SID1234535298]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Filing, 10-Q, ImmunoGen, OCT 30, 2015, View Source [SID:1234507858])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Filing, 10-Q, Johnson & Johnson, OCT 30, 2015, View Source [SID:1234507859])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!